Paper21084697
Oxidized low-density lipoprotein and atherosclerosis.
Steinberg D and 1 other. Arterioscler Thromb Vasc Biol, 2010. Cited by 361 papers, by iCite.
Cite this record
ConductScience Library. Oxidized low-density lipoprotein and atherosclerosis. Papers, record 21084697. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21084697
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Atherosclerosis | Major topic |
| Biomedical Research | Major topic |
| Endothelial Cells | Major topic |
| Lipoproteins, LDL | Major topic |
| Animals | |
| History, 20th Century | |
| Humans | |
| Immunity, Innate | |
| Narration | |
| Norway | |
| Oxidation-Reduction | |
| Receptors, Scavenger | |
| United States |
Source PubMed
Cited by220
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 361 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42798462 | Factors associated with sarcopenia in elderly patients with type 2 diabetes mellitus. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42798462 | PubMed |
| 42798332 | Effectiveness and safety of Breviscapine in the treatment of coronary heart disease: a meta-analysis of randomized controlled trials. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42798332 | PubMed |
| 42737545 | Interferon Regulatory Factors as Potential Therapeutic Targets in Cardiovascular Disease: Focusing on Vascular Inflammation. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42737545 | PubMed |
| 42524664 | Therapeutic potential of hydrogen-rich water (HRW) in oxidative stress-related diseases. | J Clin Biochem Nutr | 2026 | https://conductscience.org/library/papers/42524664 | PubMed |
| 42437951 | Anti-inflammatory agents in atherosclerosis-and a need for reform: Extraordinary claims require extraordinary evidence. | J Intern Med | 2026 | https://conductscience.org/library/papers/42437951 | PubMed |
| 42282966 | OxLDL-induced ferroptosis and pyroptosis in atherosclerosis: a mini review. | Front Immunol | 2026 | https://conductscience.org/library/papers/42282966 | PubMed |
| 42183881 | Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials. | Eur Heart J | 2026 | https://conductscience.org/library/papers/42183881 | PubMed |
| 42110962 | Lipoprotein(a): A Novel Risk Factor for Heart Failure and Biomarker of Prognosis? From Pathophysiology to Clinical Practice. | Card Fail Rev | 2026 | https://conductscience.org/library/papers/42110962 | PubMed |
| 42042621 | Biomarkers of Remote Ischaemic Conditioning in Stroke and Cerebral Small Vessel Disease: A Narrative Review. | NeuroSci | 2026 | https://conductscience.org/library/papers/42042621 | PubMed |
| 41745332 | Atherosclerosis: A Pathologist's Perspective. | J Cardiovasc Dev Dis | 2026 | https://conductscience.org/library/papers/41745332 | PubMed |
| 41437771 | An updated overview of lipid-regulated immunobiology in macrophages. | Acta Biochim Biophys Sin (Shanghai) | 2026 | https://conductscience.org/library/papers/41437771 | PubMed |
| 41322488 | Value of lipoprotein(a) in predicting severity of coronary artery stenosis in patients with chronic coronary artery disease: a cross-sectional study in Vietnam. | Front Cardiovasc Med | 2025 | https://conductscience.org/library/papers/41322488 | PubMed |
| 40833492 | Anti-Atherogenic Mechanisms and Therapies. | Curr Atheroscler Rep | 2025 | https://conductscience.org/library/papers/40833492 | PubMed |
| 40821628 | PCSK9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome. | J Med Biochem | 2025 | https://conductscience.org/library/papers/40821628 | PubMed |
| 40681803 | Coronary plaque healing: a safety net or a hazard indicator? | J Thromb Thrombolysis | 2026 | https://conductscience.org/library/papers/40681803 | PubMed |
| 40577270 | Synergistic effects of notoginsenoside R1 and saikosaponin B2 in atherosclerosis: A novel approach targeting PI3K/AKT/mTOR pathway and macrophage autophagy. | PLoS One | 2025 | https://conductscience.org/library/papers/40577270 | PubMed |
| 40552286 | Atherosclerosis: from lipid-lowering and anti-inflammatory therapies to targeting arterial retention of ApoB-containing lipoproteins. | Front Immunol | 2025 | https://conductscience.org/library/papers/40552286 | PubMed |
| 40427454 | The Dark Triad of Particulate Matter, Oxidative Stress and Coronary Artery Disease: What About the Antioxidant Therapeutic Potential. | Antioxidants (Basel) | 2025 | https://conductscience.org/library/papers/40427454 | PubMed |
| 40425644 | The influence of habitual tooth brushing frequency on individuals diagnosed with coronary artery disease. | Sci Rep | 2025 | https://conductscience.org/library/papers/40425644 | PubMed |
| 40404619 | The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/40404619 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/21084697
GET https://conductscience.org/api/papers/v1/21084697/cited_by?page=2